Clinical trials: Thromboembolic Disease
Spinal Cord Injuries, Venous Thromboembolism
Apixaban For Thromboprophylaxis In Patients With Acute Spinal Cord Injury
Thromboprophylaxis options are limited for patients with acute spinal cord injury (SCI) and there are no studies on direct oral anticoagulants (DOACs) for thromboprophylaxis in this population.
- Trial name
- NCT03200613
- Testing
- Apixaban, Low molecular weight heparin
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- McMaster University
Lung Cancer, Venous Thromboembolism
Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
The purpose of this observational study is to explore the incidence, risk factors, and relationship with therapeutic outcomes of VTE (venous thromboembolism) and ATE (arterial thromboembolism) associated with immune checkpoint…
- Conditions
- Lung Cancer, Venous Thromboembolism, Arterial Thromboembolism, Immune Checkpoint Inhibitors (ICIs)
- Trial name
- NCT06950697
- Where
- 5 sites in China
- Volunteers
- 2,400 people
- Sponsor
- Beijing Chao Yang Hospital
Thromboembolism, Bleeding
Anticoagulant After Implantation of Biological Aortic Valve Comparing With Aspirin
The optimal medical strategy for prevention of thromboembolic events after bioprosthetic aorta valve replacement (BAVR) remains controversial.
- Trial name
- NCT01452568
- Testing
- Aspirin, Warfarin
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Venous Thromboembolism, Ovarian Neoplasms
Venous Thromboembolic Complications in Ovarian Cancer
Objectives of the study are: To estimate the incidence of venous thromboembolism (VTE) in a cohort of women with suspected ovarian cancer and evaluate changes in the coagulation system in case of benign or malignant disease.
- Conditions
- Venous Thromboembolism, Ovarian Neoplasms, Ovarian Cancer, Deep Vein Thrombosis
- Trial name
- NCT02480790
- Where
- Denmark
- Volunteers
- 98 people
- Sponsor
- Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery
Venous Thromboembolism, Pelvic Surgery
Venous Thrombo-embolic Complication prévention in Pelvic Surgery
Pelvic fracture surgery are very high thrombotic risk surgery with about 10% to 50% venous thrombo embolic complications and 0.5% to 10% of pulmonary embolism. The ST JOSEPH's Hospital have almost 60 cases per year .
- Trial name
- NCT03535428
- Testing
- VENOUS exploration
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Fondation Hôpital Saint-Joseph
PE - Pulmonary Embolism, PE - Pulmonary Thromboembolism
FlowTriever for Acute Massive Pulmonary Embolism (FLAME)
To evaluate treatment outcomes of patients diagnosed with high-risk (massive) pulmonary embolism
- Trial name
- FLAME (NCT04795167)
- Where
- 11 sites in United States
- Volunteers
- 115 people
- Sponsor
- Inari Medical
High Bleeding Risk, Hemorrhage
Efficacy of Intermittent Pneumatic Compression (IPC) on Venous Thromboembolism Incidence in Intensive Care Unit (ICU) Patients With High Bleeding Risk
This multicentre open-label randomized parallel-group trial aims to evaluate the association intermittent pneumatic compression + elastick stockings versus elasting stockings alone on symptomatic or asymptomatic venous…
- Trial name
- CIREA1 (NCT00740844)
- Testing
- Intermittent pneumatic compression of the lower limbs
- Where
- 10 sites in France
- Volunteers
- 408 people
- Sponsor
- University Hospital, Brest
Venous Thromboembolism
Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients
The primary purpose of this study is to demonstrate that a continuous infusion of intravenous (IV) heparin (UFH) for Venous thromboembolism (VTE) prophylaxis will restore prophylactic levels of heparin in high-risk critically ill…
- Trial name
- NCT02707263
- Testing
- intravenous continuous infusion of heparin (IV UFH), Subcutaneous Heparin
- Where
- United States
- Sponsor
- NYU Langone Health
Venous Thromboembolism, Deep-Vein Thrombosis
Pro-coagulant Markers and Anticoagulant Failure in Cancer Patients at Risk for Recurrence of Venous Thromboembolism
The presence of clots in the veins of arms and/or legs or lungs of Cancer patients decreases their quality of life, delays their treatment and may cause death.
- Conditions
- Venous Thromboembolism, Deep-Vein Thrombosis, Pulmonary Embolism, Cancer
- Trial name
- REMARK (NCT01602445)
- Where
- 5 sites in Canada
- Volunteers
- 700 people
- Sponsor
- Ottawa Hospital Research Institute
Venous Thromboembolism
Venous Thromboembolism During COVID-19 Pandemic: Evaluation of the Association With the Vaccine and COVID-19 Infection
Observational, spontaneous, retrospective, multicenter national study for adult patients, not hospitalized, attending the Thrombo-Embolic Emergency Clinic of the Angiology and Coagulation Disorders Unit (SSD Angiologia e Malattie…
- Trial name
- NCT06806800
- Where
- Italy
- Volunteers
- 16,000 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Postpartum Hemorrhage, Venous Thromboembolism
Timing of Thromboprophylaxis After Postpartum Hemorrhage
Postpartum hemorrhage is a leading cause of maternal morbidity and mortality worldwide. Women who experience severe postpartum hemorrhage are at increased risk of both recurrent bleeding and venous thromboembolism.
- Conditions
- Postpartum Hemorrhage, Venous Thromboembolism, Pulmonary Embolism, Deep Vein Thrombosis
- Trial name
- NCT07689136
- Testing
- Pharmacologic Thromboprophylaxis
- Where
- Tunisia
- Volunteers
- 236 people
- Sponsor
- University Tunis El Manar
Venous Thromboembolism
Pharmacokinetics of Enoxaparin in Intensive Care Patients
To evaluate the pharmacokinetics of the thromboprophylactic agent enoxaparin in critically ill patients by comparing plasma anti-factor Xa activity when enoxaparin is administered either as a continuous intravenous infusion or…
- Trial name
- NCT02095509
- Testing
- Enoxaparin
- Where
- 2 sites in Finland
- Volunteers
- 39 people
- Sponsor
- Tampere University Hospital
Thromboembolic Events
Association of Genetic Variants With Risk of Stroke in Patients With Atrial Fibrillation Off-anticoagulation
Life-long therapy with oral anticoagulants (OAC) is strongly recommended in AF patients receiving left atrial appendage isolation (LAAI) to prevent thromboembolic (TE) events.
- Trial name
- GSAF (NCT04115436)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Texas Cardiac Arrhythmia Research Foundation
Intracranial Embolism
Electrical Cardioversion of Recent Onset Atrial Fibrillation - Silent Thromboembolic Events, Reverse Atrial Remodeling
The purpose of this study is to study the effects of transthoracic electrical cardioversion for restoration of sinus rhythm in patients who present with recent onset atrial fibrillation, with regard to new silent cerebral…
- Trial name
- ECAF-STAR (NCT02955004)
- Testing
- Electrical cardioversion
- Where
- 3 sites in Sweden
- Volunteers
- 43 people
- Sponsor
- Uppsala University Hospital
Thrombosis
Sickle Cell Trait and the Risk of Venous Thromboembolism
The purpose of this trial is to investigate D-Dimer levels, a surrogate marker of venous thromboembolism, in pregnant/postpartum white women as compared to pregnant/postpartum black women, and pregnant/postpartum women with…
- Trial name
- SCT&DVT (NCT01148940)
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
Hypertension, Pulmonary
A Study Investigating Routine Practice of Chronic Thromboembolic Pulmonary Hypertension Management in EMEA Countries
The aim of the registry is the assessment of the diagnosis and treatment of CTEPH (Chronic Thromboembolic Pulmonary Hypertension) in EMEA (Europe/Middle East/Africa) countries.
- Trial name
- EMEA CTEPH (NCT02637050)
- Testing
- Standard of care
- Where
- 6 sites in Kazakhstan, Kyrgyzstan and 4 more
- Volunteers
- 231 people
- Sponsor
- Bayer
Venous Thromboembolic Disease
Value of D-dimer Combined With Other Thrombus Molecular Markers in Risk Assessment of VTE in Hospitalized Patients
The occurrence of VTE in hospital is an important cause of unexpected death of inpatients, and has become a serious problem faced by hospital managers and clinical medical staff.Under the target of "Improving the Standard…
- Trial name
- NCT05515549
- Testing
- Venous blood was collected from patients under fasting state to detect the level of thrombus molecular markers
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Qianfoshan Hospital
Venous Thromboembolism
Platelet FcGammaRIIa and Risk of Venous Thromboembolism in Cancer
Thrombosis is common and contributes significantly to morbidity and mortality in patients with cancer. At least 20% of patients with cancer develop venous thromboembolism (VTE) and another 5% will experience acute arterial…
- Trial name
- NCT05240508
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- University of Vermont
Deep Vein Thrombosis, Pulmonary Embolism
Prophylaxis of Thromboembolic Complications Trial: Thromboprophylaxis Needed in Below Knee Plaster Cast Immobilization for Ankle and Foot Fractures
Objective: The purpose of this study is to determine the need for thromboprophylaxis in patients with a fracture of the lower extremity being treated conservatively in a below-knee plaster cast and to assess if both of the two…
- Trial name
- PROTECT (NCT00881088)
- Testing
- Nadroparin, Fondaparinux
- Where
- 5 sites in Netherlands
- Volunteers
- 669 people
- Sponsor
- Red Cross Hospital Beverwijk
Anticoagulant Antagonists, Vitamin K and Other Coagulants Causing Adverse Effects in Therapeutic Use, Atrial Fibrillation
Evaluation of Oral Anticoagulation With Vitamin K Antagonists - The thrombEVAL Study Programme
Since decades, oral anticoagulation (OAC) with vitamin K antagonists (VKA) is an established therapy for both prevention and treatment of thromboembolism in daily clinical routine.
- Conditions
- Anticoagulant Antagonists, Vitamin K and Other Coagulants Causing Adverse Effects in Therapeutic Use, Atrial Fibrillation, Venous Thromboembolism
- Trial name
- thrombEVAL (NCT01809015)
- Where
- Germany
- Volunteers
- 2,318 people
- Sponsor
- Johannes Gutenberg University Mainz
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.